Therapeutic approaches to familial Mediterranean fever. What do we know and where are we going to?

Clinical and Experimental Rheumatology

Volumn 22, Issue 4 SUPPL. 24, 2004, Pages

  Amital, Howard ^a   Ben Chetrit, Eldad ^a,b  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogenic bone marrow transplantation; Alpha interferon; Colchicine; Familial Mediterranean fever (FMF); Thalidomide

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; COLCHICINE; CORTICOTROPIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PREDNISONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; L SELECTIN; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; AUTOSOMAL RECESSIVE DISORDER; CELL LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ERYSIPELAS; FAMILIAL MEDITERRANEAN FEVER; FEMALE INFERTILITY; FEVER; HEPATITIS B; HUMAN; INFLAMMATION; LEUKOPENIA; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; TERATOGENICITY; TRISOMY 21; BONE MARROW TRANSPLANTATION; DRUG ANTAGONISM; IMMUNOLOGY; CONGENITAL DYSERYTHROPOIETIC ANEMIA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; MYOPATHY; PROTEIN EXPRESSION; DRUG RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT;

ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; COLCHICINE; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INTERFERON-ALPHA; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5444228389     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. HELLER H, SOHAR E, SHERF L: Familial Mediterranean fever. Arch Intern Med 1958; 102: 50-71.
2. DRENTH JP, van der MEER JW: Hereditary periodic fever. N Engl J Med 2001; 345: 1748-57.
3. BEN-CHETRIT E, LEVY M: Familial Mediterranean fever. Lancet 1998; 351: 659-64.
4. GOLDFINGER SE: Colchicine for familial Mediterranean fever. N Eng J Med 1972; 287: 1302.
5. MOLAD Y: Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002; 4: 252-6.
6. ZEMER D, REVACH M, PRAS M et al.: A controlled trial of colchicine in preventing attacks of Familial Mediterranean Fever. N Engl J Med 1974; 291: 932-4.
7. ZEMER D, PRAS M, SOHAR E, MODAN M, CABILI S, GAFNI J: Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001-5.
8. BESSIS M, BRETON-GORIUS J: Rapports entre noyau et centrioles dans les granulocytes étalalés. Rúle des microtubules. Nouvelle Revue Francaise d'Hématologie 1967; 7: 601-20.
9. SACKETT DL, VARMA JK: Molecular mechanism of colchicine action: induced local unfolding of b-tubulin. Biochemistry 1993; 32: 13560-5.
10. VANDECANDELAERE A, MARTIN SR, ENGELBORGHS Y: Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules. Biochem J 1997; 323: 189-96.
11. LI Z, DAVIS GS, MOHR C: Inhibition of LPS-induced tumor necrosis factor-α production by colchicine and other microtubules disrupting drugs. Immunobiology 1996; 195: 624-9.
12. DING AH, PORTEU F, SANCHEZ E, NATHAN CF: Down-regulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolarizing agents. J Exp Med 1990; 171: 715-7.
13. CRONSTEIN BN, MOLAD Y, REIBMAN J: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994-1002.
14. PAYA M, TERENCIO MC, FERRANDIZ ML, ALCARAZ MJ: Involvement of secretory phospholipase A2 activity in the zymosan air pouch model of inflammation. Br J Pharmacol 1996; 117: 1773-9.
15. ZURIER RB, HOFFSTEIN S, WEISSMANN G: Mechanisms of lysosomal enzyme release from human leukocytes: I, effect of cyclic nucleotides and colchicine. J Cell Biol 1973; 58: 27-41.
16. WRIGHT DG, MALAWISTA SE: Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylates. Arthritis Rheum 1973; 16: 749-58.
17. BEN-CHETRIT E, FISCHEL R, HINZ B, LEVY M: The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. Rheumatol Int 2004 (in press).
18. SARALIOGLU M, SARALIOGLU H, OZEN S, ERKOC R, GUL A: Colchicine-induced myopathy in a teenager with familial Mediterranean fever. Ann Pharmacother 2003; 37: 1821-4.
19. EHRENFELD M, BRZEZINSKI A, LEVY M, ELIAKIM M: Fertility and obstetric history in patients with familial Mediterranean fever on long term colchicines therapy. Br J Obstet Gynaecol 1987; 94: 1860-191.
20. RABINOVITCH O, ZEMER D, KUKIA E, SOHAR E, MASHIACH S: Colchicine treatment in conception and pregnancy: two hundred and thirty one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 22: 245-6.
21. BEN-CHETRIT E, LEVY M: Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62: 916-9.
22. BEN-CHETRIT E, BERKUN Y, BEN-CHETRIT EL, BEN-CHETRIT A: The outcome of pregnancy in wives of men with familial Mediterranean fever treated with colchicine. Semin Arthritis Rheum 2004 (in press).
23. BEN-CHETRIT E, SCHERRMANN JM, LEVY M: Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39: 1213-7.
24. LIDAR M, KEDEM R, LANGEVITZ P, PRAS M, LIVNEH A: Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol 2003; 30: 2620-3.
25. LIDAR M, SCHERRMANN JM, CHETRIT A, NIEL E, GERSHONI R, LIVNEH A: Clinical, genetic, pharmacokinetic and socioeconomical characterization of colchicine nonresponsiveness in FMF [abstract]. Clin Exp Rheumatol 2002; 20 (Suppl. 26): 88.
26. CHAPPEY ON, NIEL E, WAUTIER JL et al.: Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993; 54: 360-7.
27. OZEN S, UCKAN D, BASKIN E et al.: Increased neutrophil apoptosis during attacks of familial Mediterranean fever. Clin Exp Rheumatol 2001; 19 (Suppl. 24): S68-71.
28. TANKURT E, TUNCA M, AKBAYLAR H, GONEN O: Resolving familial Mediterranean fever attacks with interferon alpha. Br J Rheumatol 1996 35: 1188-9.
29. TUNCA M, TANKURT E, AKBAYLAR AKPINAR H, AKAR S, HIZLI N, GONEN O: The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997; 36: 1005-8.
30. CALGUNERI M, APRAS S, OZTURK MA, ERTENLI I, KIRAZ S: The efficacy of the interferon alfa on colchicines resistant familial Mediterranean fever (FMF). Clin Exp Rheumatol 2002; 20: S106 (Abstract).
31. TUNCA M, AKAR S, SOYTURK M et al.: The effect of interferon alpha administration on acute attacks of familial Mediterranean fever, a double blind and placebo controlled trial. Clin Exp Rheumatol (in press).
32. SEYAHI E, OZDOGAN H, MASATLIOGLU S, YAZICI H: Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol 2002; 20 (Suppl. 26): S43-4.
33. DRENTH JP, VONK AG, SIMON A et al.: Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper IgD and periodic fever syndromes: a double-blind, placebo-controlled trial. J Pharmacol Exp Ther 2001; 298: 1221-6.
34. MILLEDGE J, SHAW PJ, MANSOUR A et al.: Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. Blood 2002; 100: 774-7.
35. TOUITOU I, BEN-CHETRIT E, GERSHONI-BARUCH R et al.: Allogenic bone marrow